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Peripheral vascular responses to
acetylcholine as a predictive tool for
response to cholinesterase inhibitors in
Alzheimer’s disease
Peter J. Connelly1, Fiona Adams2, Ziad I. Tayar3 and Faisel Khan2*
Abstract
Background: Cholinesterase inhibitors remain the first line therapy for people with mild to moderate Alzheimer’s
disease (AD). Response is modest and difficult to predict from pre-treatment characteristics. We hypothesise that
skin vascular response to iontophoresis of acetylcholine, which is partly determined by the level of cholinesterase
activity, may be a pre-treatment measure that could predict response to therapy.
Methods: Twenty-four people with probable AD underwent iontophoresis of acetylcholine to the volar surface of the
forearm skin prior to treatment with a cholinesterase inhibitor. The peak skin vascular response and the resolution to
baseline levels were measured using laser Doppler perfusion imaging. Response to treatment was assessed after 6
months using criteria from the National Institute for Health and Care Excellence (NICE) and iontophoresis with
acetylcholine was repeated. Blindness between clinical and laboratory assessments was maintained.
Results: Fourteen out of twenty-four people responded to treatment using NICE criteria. By comparison to non-
responders, responders to treatment had a faster resolution to baseline from acetylcholine-induced vasodilation prior
to treatment, which slowed with treatment. In this pilot study there was a high level of accuracy in the classification of
response using this variable. No baseline cognitive or functional measures discriminated end-point responders from
non-responders.
Conclusion: Cholinesterase inhibitors are well tolerated but the number of people with adverse effects would be reduced if
it was possible to predict response. The role of vasodilator response to acetylcholine and recovery as a potential biomarker
for efficacy of treatment should now be evaluated and may possibly be of relevance in stratifying samples for interventional
studies in AD and other forms of dementia. We feel that a more definitive study is now justified.
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Background
Cholinesterase inhibitors (Donepezil, Rivastigmine and
Galantamine) are the first line therapy for people with
mild to moderate Alzheimer’s disease (AD). Beneficial ef-
fects have been shown on intellectual function, day-to-day
abilities and social behaviour for all three drugs [1]. How-
ever, only approximately 40% of people who take these
drugs have a good response [1]. It remains extremely
difficult to predict in advance who might respond though
an association between pre-treatment processing speed
and response has been demonstrated [2]. Improved re-
gional cerebral blood flow (rCBF) has also been correlated
with clinical improvement [3–5], though there is dispute
over the baseline characteristics of rCBF which might be
associated with response to treatment [6, 7].
Altered skin microvascular reactivity has been described
in AD [8, 9] suggesting that skin microvascular reactivity
might be useful in the diagnosis of AD. A reduced skin
vasodilator response to iontophoresis of acetylcholine has
been described in untreated patients with mild AD
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compared with control subjects [8], while a significantly
enhanced response in patients treated with Donepezil by
comparison to untreated AD patients has also been found
[10]. Our group have previously shown that the duration of
the skin vascular response to iontophoresis of acetylcholine,
in particular the recovery to baseline, is partly determined
by the level of cholinesterase activity [11, 12]. AD is known
to be associated with lower levels of acetylcholine. Conse-
quently, less acetylcholine will be available for hydrolysis
and circulating acetylcholinesterase (AChE) levels will be
potentially higher in people with AD. We therefore
hypothesised that a person with a relatively fast acetylcho-
line recovery response could be expected to have high cho-
linesterase activity and therefore might be a good candidate
for response to cholinesterase inhibitor treatment.
This study attempts to identify the characteristic pattern
of change in peripheral blood flow following exposure to
iontophoresis of a standard dose of acetylcholine and assess
its association with response to cholinesterase inhibitor
therapy in people with AD. In particular, we sought to de-
termine whether there a difference over 6months in the
magnitude of change in blood flow between people with
AD classed as “responders” or “non-responders” to cholin-
esterase inhibitor therapy and whether blood flow responses
prior to treatment predict response to cholinesterase inhibi-
tors in patients with AD. The identification of a marker for
‘good responders’ to cholinesterase inhibition would im-
prove the cost-benefit of this class of drug as well as redu-
cing risks in those unlikely to respond to treatment.
Methods
The study was of pragmatic design and with the main in-
clusion criterion being diagnosis of probable AD by a Con-
sultant Psychiatrist or Senior Trainee using ICD-10 criteria
as is standard practice in the local Memory Service in Tay-
side after assessment of the chronology of key symptoms
including intellectual, functional and social change and,
where appropriate, neuroimaging. The decision to prescribe
a cholinesterase inhibitor, and the choice of drug, resided
with the clinician in charge of the patient’s clinical care.
Participants were invited to enrol in the study at the point
of diagnosis. Only those judged to have capacity to consent
were included. All participants gave written informed con-
sent to the study, which was approved by the East of
Scotland Research Ethics Service (REC reference 11/AL/
0259). Since all patients who are suitable for cholinesterase
inhibitor therapy are commenced on those drugs it was not
possible to include a matched control group.
For the purposes of this study, participants who con-
sented to participate underwent assessment using the
Mini-Mental State Examination (MMSE) [13], the
Nurses’ Observation Scale for Geriatric patients (NOS-
GER) [14] and a version of the Digit Symbol Substitution
Test (DSST) [15]. The Instrumental Activities of Daily
Living and Social Behaviour sub-scales of the NOSGER
were extracted from the full score as these have been
used in other local studies as an index of change involv-
ing with no memory questions. The study was approved
by the East of Scotland Research Ethics Committee (ref
11/AL/0259) and conducted according to the principles
of the Declaration of Helsinki. Recruitment ran from
October 2011 to May 2014.
Since the study was designed to reflect actual clinical
practice in the use of cholinesterase inhibitors, no exclu-
sions were made on the use of concurrent drug therapy,
smoking status, hypertension or diabetes. Similarly there
was no set range for Mini Mental State Examination
(MMSE) scores at baseline; we felt this was justified be-
cause an association between MMSE scores and vaso-
dilator response was not found in a study by Maltz et al.
[10] in similar patients. Patients were excluded if they
had medical conditions known to interfere with acetyl-
choline metabolism or were likely to react adversely to
skin stimulation. Additionally, we excluded patients if
they were taking medication whose primary action was
anti-cholinergic and was being used for a medical condi-
tion in which anti-cholinergic action was the desired
intervention e.g. oxybutynin for irritable bladder. Smok-
ing and caffeine intake were prohibited on the day of
skin testing until all tests had been completed.
Prior to commencing treatment with a cholinesterase
inhibitor (usually within 10 working days) patients had
baseline skin blood flow responses to iontophoresis of
acetylcholine and sodium nitroprusside performed by an
experienced Research Fellow (FA) or under her supervi-
sion. All tests were conducted in the same laboratory
setting within Ninewells Hospital, Dundee, UK. All as-
sessments were undertaken in the morning to control
for the diurnal variation of vascular responses [16].
Blindness between the results of any cognitive, func-
tional or global assessments and the results of skin flow
measures was maintained throughout the study.
Iontophoresis of vasoactive chemicals Experiments
were conducted in a temperature-controlled room (22-23
°C). Following a 20-min equilibration period, baseline skin
perfusion was measured for 2min. Skin blood flow re-
sponses to iontophoresis of acetylcholine and sodium ni-
troprusside were measured on the volar aspect of the
forearm using laser Doppler perfusion imaging (moorLDI,
Moor Instruments Ltd., Devon, UK) according to our pre-
viously described protocol [12, 17]. Scans at 30 s intervals
were used to build colour-coded image representing skin
perfusion in two dimensions. From these images, a relative
measure of skin blood flow was determined (termed laser
Doppler flux) and expressed in perfusion units (PU).
While the recovery of the acetylcholine response is partly
determined by levels of cholinesterase, the peak response
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is governed by the endothelium-dependent production of
nitric oxide. Therefore, as a control, the skin blood flow re-
sponse and recovery to iontophoresis of sodium nitroprus-
side were determined since these results are determined by
the endothelium-independent production of nitric oxide.
Iontophoresis was used to transport 1% acetylcholine
(Miochol-E, Novartis, Surrey, UK) for 80 s using a 0.1 mA
anodal current (delivering a dose of 8 m-Coulombs (mC))
across the skin within the area of the iontophoresis cham-
ber (Moor Instruments Ltd., Devon, UK), which consisted
of a Perspex ring of internal diameter 20mm. After deter-
mining the peak blood flow response to acetylcholine, the
subsequent recovery of blood flow from this level back to
baseline was recorded for up to 30min to allow the rate of
decay to be established. Following this, 1% sodium nitro-
prusside (Rottapharm, Barcelona, Spain) was iontophor-
esed at an adjacent site for 80 s using a 0.1mA cathodal
current. To determine the decay response, the time taken
for the blood flow to return to 50% of the peak value for
acetylcholine was calculated.
After the initial measurements of blood flow response
to iontophoresis of acetylcholine and sodium nitroprus-
side patients took the first dose of cholinesterase inhibitor
medication. All three drugs (Donepezil, Rivastigmine and
Galantamine) were used in the study. At 6months, partic-
ipants were assessed clinically by the Consultant psych-
iatrist or senior psychiatric trainee responsible for the
clinical care of the patient to determine whether they were
considered to have responded to the treatment or not,
with classification as ‘responder’ or ‘non-responder’ based
on the change in MMSE, NOSGER sub-scales, DSST and
a global assessment of change including carer/family views
(see Table 1) as recommended by NICE [18]. Blood flow
responses were re-measured as described above.
Statistical analysis Differences in vascular responses to
acetylcholine and sodium nitroprusside between good and
poor responders was analysed using two way analysis of
variance and unpaired t-tests. Within group differences
were analysed using paired t-tests. Correlations were per-
formed using Pearson’s correlation coefficient. P < 0.05
was chosen as the level of significance. All comparisons
were undertaken using SPSS Version 22. Analysis of cog-
nitive and functional scales or blood flow data was per-
formed by individuals who had remained blind to the
results from the other domains throughout the study.
Results
Twenty-six patients were enrolled and twenty-four com-
pleted the follow-up visit at 6 months. Data is therefore
presented only for those participants who completed
both visits. The main reason for two participants with-
drawing from the study was a reluctance to travel to the
laboratory site. No study procedure-related adverse
events were recorded. Baseline clinical characteristics of
the patients are shown in Table 1.
Table 2 shows the data in all patients for clinical re-
sponses and vascular responses at baseline and following
6 months of treatment. No significant differences were
observed for any of the clinical assessments or vascular
parameters measured at baseline versus 6-months’
follow-up, although there was a trend for an increase in
peak responses to acetylcholine (P = 0.08) and sodium
nitroprusside (P = 0.08) at 6 months.
Response to treatment After 6 months’ treatment, 14/
24 (58.33%) were classified as “responders” to cholin-
esterase therapy. There were no significant differences in
the basic clinical characteristics between responders and
non-responders other than body mass index. (Table 1).
Table 3 shows the data for responders and non-responders
for clinical and vascular responses at baseline and following
6months of treatment. No significant differences were ob-
served for any of the vascular parameters measured at base-
line versus 6-months’ in non-responders.
Non-responders showed a decline in values for all four
clinical variables whereas responders showed improve-
ment in all four, although only IADL/SB and DSST scores
among the non-responders were significantly different
from baseline within the groups. Analysis of covariance
showed significant differences between the change in
scores for all variables from baseline to 6-months
follow-up between the two groups after controlling for
baseline scores (MMSE P = 0.013, NOSGER IADL/SB P =
0.031, NOSGER Total P = 0.013, DSST P = 0.005).
Within the responder group, there were significant in-
creases in the peak acetylcholine response (P < 0.01) and
peak sodium nitroprusside response (P < 0.005) between
responses at baseline versus follow-up at 6 months, and
also a significant increase in the time course of acetyl-
choline 50% decay (P < 0.05) indicative of a slower decay
response. The change in peak acetylcholine response,
peak sodium nitroprusside response and acetylcholine
50% decay from baseline to 6-month follow-up was sig-
nificantly different between non-responders and re-
sponders after adjusting for baseline values, BMI and
gender (P < 0.002, P < 0.01, and P < 0.001, respectively).
Within the non-responder group, there were no signifi-
cant differences in peak acetylcholine response, peak so-
dium nitroprusside response, or in the time course of
acetylcholine 50% decay before and after treatment.
Comparing responses between non-responders and re-
sponders at baseline and at follow-up at 6 months
showed that acetylcholine 50% decay was significantly
faster in responders (230 ± 38 s versus 400 ± 60 s, P <
0.05) indicating a faster decay in patients who were sub-
sequently classified as responders. No other differences
Connelly et al. BMC Neurology           (2019) 19:88 Page 3 of 7
were observed between the two groups at baseline or at
6 months follow-up.
There were no significant correlations between the
baseline variable values in Table 1 and vascular re-
sponses to acetylcholine and sodium nitroprusside or in
the time course of acetylcholine 50% decay in all pa-
tients at baseline and 6-months follow-up or within the
non-responder and responders groups at any time point.
However, there were negative correlations between base-
line peak and decay values for acetylcholine and change
scores over time for MMSE, NOSGER IADL/SB, NOS-
GER Total and DSST, which were significant for NOS-
GER IADL/SB in the total group (r = − 0.575, P = 0.006
and r = − 0.435, P = 0.049 for peak acetylcholine and
decay, respectively) and for both NOSGER IADL/SB (r
= − 0.817, P = 0.001 for peak acetylcholine) and NOS-
GER Total (r = − 0.704 P = 0.016 for peak acetylcholine
response) in the responders. No comparisons were sig-
nificant in non-responders.
Receiver operating characteristic curve analysis between
non-responders and responders versus baseline acetylcho-
line peak or decay revealed an area under curve value of
0.583 for peak and 0.800 for decay with a cut-point for
decay of 242 s showing sensitivity of 0.90 and specificity of
0.77 for categorisation of response group. 10/14 re-
sponders and 1/10 non-responders had a baseline decay
time ≤ 242 s. Bivariate logistic regression around this
cut-point showed that 79.2% of patients were correctly
categorised (positive predictive value = 71.4%, negative
predictive value 90%) (Wald statistic = 6.64, df = 1, P =
0.010). Odds ratio was 22.50 (95% CI 2.11–240.48).
Discussion
The findings from this study show that the clinical re-
sponse to cholinesterase inhibitors over a 6 month
period is modest as expected, although there are differ-
ent patterns in responders versus non-responders. No
baseline cognitive or functional variable was able to dis-
criminate end-point responders from non-responders at
a statistically significant level. There was also no rela-
tionship between perfusion parameters and severity of
cognitive or functional impairment at baseline. By con-
trast, baseline decay in recovery from vasodilation asso-
ciated with acetylcholine discriminated the response
groups with a high degree of accuracy. There were nega-
tive correlations between baseline decay and the change
in each clinical variable, suggesting the possibility that
the degree of inhibition of AChE may be related to re-
sponse as previously reported with respect to CSF [19],
which is considerable more invasive to measure. As a
rapidly measured dynamic variable, our test may also
prove more useful that measuring red cell cholinesterase
inhibition, which has been shown to be an unreliable
marker for the activity of cholinesterase inhibitors [20].
Recovery of the vasodilator response to iontophoresis
of acetylcholine is probably dependent upon various fac-
tors, one of which will be the vascular expression of cho-
linesterase. We have previously shown that high
Table 1 Baseline clinical characteristic of AD patients. Values are means ± SE
All (n = 24) Non-responder (n = 10) Responder (n = 14)
Age (years) 77.6 ± 1.2 78.8 ± 2.0 76.6 ± 1.6
Male/female (No.) 12/13 3/7 9/5
Height (m) 1.62 ± 0.02 1.59 ± 0.03 1.65 ± 0.02
Weight (Kg) 72.3 ± 2.7 77.6 ± 4.9 69.1 ± 3.5
Body mass index (Kg/m2) 27.3 ± 1.0 30.5 ± 1.6 25.2 ± 1.0*
Systolic blood pressure (mmHg) 149 ± 4 150 ± 5 145 ± 6
Diastolic blood pressure (mmHg) 76 ± 2 80.1 ± 3 74.4 ± 3
Heart rate (beats/min) 66 ± 2 72 ± 3 64 ± 3
* P < 0.01
Table 2 Changes in clinical assessments and vascular responses
(in perfusion units) to acetylcholine and sodium nitroprusside in
all patients (n = 24), and the subsequent time course of decay in
acetylcholine response to 50% of the peak value at baseline and
following 6months of treatment. Values are means ± SE
Baseline 6 months
Clinical parameters
MMSE 24.0 ± 0.6 24.7 ± 0.6
NOSGER IADL/SB 37.8 ± 1.6 37.5 ± 1.7
NOSGER Total 118.9 ± 3.7 118.7 ± 3.3
DSST 21.4 ± 2.3 21.9 ± 2.1
Vascular responses
Basal perfusion (PU) 40 ± 11 47 ± 12
Peak acetylcholine response (PU) 334 ± 40 389 ± 31
Peak sodium nitroprusside response (PU) 274 ± 34 337 ± 33
Acetylcholine 50% decay (secs) 318 ± 41 321 ± 32
MMSE Mini Mental State Exam
NOSGER Nurses Observation Scale for Geriatric Patients IADL/SB combined
score (max 50, higher scores are better)
NOSGER Total Nurses Observation Scale for Geriatric Patients Total Score (max
150, higher scores are better)
DSST Digit Symbol Substitution Test over 90 s
Connelly et al. BMC Neurology           (2019) 19:88 Page 4 of 7
cholinesterase activity is normally associated with a
quicker recovery in the acetylcholine-induced blood flow
response [12], while a prolongation of the decay of
acetylcholine-stimulated hyperaemia in response to topical
edrophonium administration in the forearm of normal hu-
man subjects has also been shown [21]. The prolongation
of decay of the iontophoretic response to acetylcholine
through an effect on inhibition of cholinesterase via mala-
thion lends further support to the link between skin re-
sponse and vascular cholinesterase activity [22].
The fact that the peak acetylcholine response fol-
lowing a single dose application is not statistically dif-
ferent between non-responders and responders at
baseline suggests that muscarinic receptor density on
the endothelium is comparable and that there were
no significant differences in endothelial function.
Additionally, the finding that responses to sodium ni-
troprusside were also similar between non-responders
and responders at baseline implies that general vascu-
lar function was comparable in the two groups.
Although BMI was significantly greater in non-responders
than responders at baseline, we did not find any correlation
between this and acetylcholine decay and cannot comment
on what influence this might have on the response to treat-
ment. However, an important point to note is that the pur-
pose of our study was not to determine what factors (e.g.
BMI, blood pressure, gender) influence outcome to treatment,
but rather to see whether we could find a biomarker indica-
tive of response to treatment based on examining the periph-
eral vascular response to iontophoresis of acetylcholine.
We appreciate that additional factors that were not
assessed in this study could change the cholinergic sta-
tus and alter the capacity to hydrolyse acetylcholine and
thus the responses found in our test [23, 24], but pos-
sibly also in treatment. We recognise that many drugs
have anticholinergic actions of differing potency [25–27]
and that some of these were used for concomitant med-
ical disorders, but given the sample size in our pilot
study it is unrealistic to use potency as a variable in our
analyses. In our larger planned study we will address this
issue more closely. Participants who had previously been
treated with cholinesterase inhibitors or who had med-
ical conditions known to interfere with acetylcholine
metabolism were excluded.
We are also aware that a peripheral test can only be a
proxy for central activity and a weakness of our pilot
study is that it did not allow for detailed examination of
the mechanism which might affect response including
potentially important genomic findings in single nucleo-
tide polymorphisms (SNPs) in both the acetyl- and bu-
tyrylcholinesterase (AChE and BChE) genes which may
have a strong influence on the responses found in our
test [24] but possibly also in treatment. However, the
strength of our findings is that they are generated by a
minimally-invasive test which can be performed fairly
quickly in a clinic setting and potentially provide a rapid
pragmatic guide to clinicians and patients about likeli-
hood of response to cholinesterase inhibitors. It is highly
likely that no single variable will prove to be a fully pre-
dictive measure of response but detailed mechanistic
evaluation can be explored as part of a larger follow-up
study in preparation.
Following 6-months’ of treatment, there were no sig-
nificant changes in any of the vascular function parame-
ters in the non-responders which was in contrast with
the responders who showed significant slowing in the
acetylcholine decay at 6-months compared with baseline
and also a significant improvement in vascular responses
to acetylcholine and sodium nitroprusside. We believe
that the slower decay in responders is related to a
Table 3 Changes in clinical assessments and vascular responses (in perfusion units) to acetylcholine and sodium nitroprusside in
responders and non-responders, and the subsequent time course of decay in acetylcholine response to 50% of the peak value at
baseline and following 6 months of treatment. Values are means ± SE
Non responder Responder
Baseline 6 months Baseline 6 months
Clinical parameters
MMSE 23.4 ± 1.0 23.0 ± 0.9 24.4 ± 0.6 25.9 ± 0.6
NOSGER IADL/SB 39.0 ± 2.2 35.9 ± 2.6* 36.8 ± 2.4 38.8 ± 2.2
NOSGER Total 121.8 ± 4.8 116.2 ± 4.7 116.5 ± 5.5 120.7 ± 4.7
DSST 16.6 ± 3.7 14.5 ± 3.8* 22.3 ± 2.5 25.1 ± 1.8
Vascular responses
Basal perfusion (PU) 49 ± 12 51 ± 13 41 ± 10 43 ± 11
Peak acetylcholine response (PU) 345 ± 77 361 ± 49 326 ± 43 409 ± 43**
Peak sodium nitroprusside response (PU) 288 ± 68 296 ± 45 265 ± 36 366 ± 50***
Acetylcholine 50% decay (secs) 400 ± 60 321 ± 32 230 ± 38¥ 332 ± 42*
* P < 0.05; ** P < 0.01; *** P < 0.005, comparing values at baseline versus 6 months within the two groups
¥ P < 0.05 comparing baseline acetylcholine 50% decay between non-responders and responders
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decrease in cholinesterase activity due to inhibition by
treatment. The reasons for the improvement in the peak
response to both acetylcholine and sodium nitroprusside
is less clear but may be related to an improvement in
endothelial function in the case of acetylcholine [8], and,
for sodium nitroprusside, due to an improvement in re-
lease of acetylcholine due to flow-mediated dilatation
following cholinesterase inhibition [28].
The observed increase in skin blood flow response to
acetylcholine and sodium nitroprusside might also re-
flect improvements in cerebral perfusion and thus con-
tribute to the positive response to treatment. Vascular
responses in the skin are thought to reflect generalised
vascular function [29]. We have previously shown that
skin vascular responses to iontophoresis of acetylcholine
and sodium nitroprusside in the forearm correlate sig-
nificantly with responses in the coronary circulation
[30], and thus it is plausible that similar improvements
could be present in cerebral vessels and thus explain the
findings on SPECT seen in earlier studies [3–5]. In this
way, improvements in cerebral blood flow could contrib-
ute to slowing of neural degeneration.
Conclusion
Though we accept that in this pilot study numbers
were small and that replication in a larger study is re-
quired, these results are encouraging and support our
hypothesis that levels of cholinesterase are higher
than in non-responders and thus treatment is more
likely to be of benefit in people with faster decay of
vasodilator response. The implications of our findings,
if replicated in a larger study which controls for pos-
sible vascular confounders and factors thought to
interact with cholinesterase activity (such as genomic
differences and blood AChE and BChE activities), are
that it may be possible to predict response to cholin-
esterase inhibitors by using a brief non-invasive test
prior to treatment. By contrast to studies relating
clinical response to changes in rCBF [3–5], our study
identifies a possible baseline variable unrelated to se-
verity of cognitive or functional impairment, rather
than measuring change in pre-defined groups.
In addition to possible longer-term benefits for
those who respond to treatment, avoiding prescription
in potential non-responders prevents exposure to po-
tential side-effects of these drugs and allows appropri-
ate care plans to be drawn up which concentrate on
non-pharmacological interventions. The role of vaso-
dilator response as a potential biomarker for treat-
ment should now be evaluated and may possibly be
of relevance in stratifying samples for interventional
studies in AD and other forms of dementia. We feel
that a more definitive study is now justified.
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